There appears to be inconclusive evidence on the potential of the novel class of glucose-lowering drugs, namely sodium glucose-linked cotransporter 2 (SGLT2) inhibitors, in stroke therapy, according to the results of a systematic review. This is because few animal studies are available, and some of the clinical studies evaluate combinations of drug treatments of SGLT2 and other drugs related to diabetes treatment.
Patients with chronic pain and those with reported misuse of opioid medications exhibit reduced hedonic capacity compared with healthy individuals, suggesting that both chronic pain and opioid misuse have a hand in anhedonia, according to a study.
Investigational drug AMO-02 (tideglusib) has a favourable risk-benefit and pharmacokinetic profile for congenital and childhood-onset type 1 myotonic dystrophy, a recent phase II study has shown. Further studies on tideglusib are warranted.
Although continuous tube feeding is effective in enhancing the tolerance of enteral nutrition, a recent study has found not enough evidence supporting its advantage in calorie intake in patients with haemorrhagic stroke.
Use of rivaroxaban, with or without aspirin, falls short of reducing the number of incident covert infarcts compared with aspirin alone in patients with stable coronary and peripheral vascular disease, according to a study.
Thyroid dysfunction during pregnancy is associated with several neurocognitive outcomes in the offspring, suggest the results of a study. Prompt examination and treatment on thyroid function is urged for pregnant women.
A new combination product (AXS-07), which consists of the triptan rizatriptan and the NSAID* meloxicam, led to rapid and sustained pain relief than treatment with either component alone or placebo in patients with a history of inadequate response to prior acute migraine treatment, according to data from the MOMENTUM study released during the AAN 2020 Meeting.
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.